514 related articles for article (PubMed ID: 26542609)
21. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
22. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
23. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
[TBL] [Abstract][Full Text] [Related]
24. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
Lyn J; Wang Y; Wang F; Shen M; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
[TBL] [Abstract][Full Text] [Related]
26. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
27. Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
Ciocca V; Bombonati A; Palazzo JP; Schulz S; Waldman SA
Histopathology; 2009 Aug; 55(2):182-8. PubMed ID: 19694825
[TBL] [Abstract][Full Text] [Related]
28. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
[TBL] [Abstract][Full Text] [Related]
29. Expression of REG4 in ovarian mucinous tumors.
Huang Q; Chen X; Lu W; Lai M; Lu B
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
[TBL] [Abstract][Full Text] [Related]
30. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma.
Liu F; Gao Z; Shen D; Zhao H; Wang C; Ye Y; Ma Y; Kong F
Pathol Res Pract; 2019 Jul; 215(7):152430. PubMed ID: 31101576
[TBL] [Abstract][Full Text] [Related]
31. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
32. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
[TBL] [Abstract][Full Text] [Related]
33. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
[TBL] [Abstract][Full Text] [Related]
34. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
[TBL] [Abstract][Full Text] [Related]
36. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
[TBL] [Abstract][Full Text] [Related]
37. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
[TBL] [Abstract][Full Text] [Related]
38. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
39. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
40. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
